Lifecore Biomedical Inc
NASDAQ:LFCR
Lifecore Biomedical Inc
Net Issuance of Common Stock
Lifecore Biomedical Inc
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lifecore Biomedical Inc
NASDAQ:LFCR
|
Net Issuance of Common Stock
$23.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
131%
|
CAGR 10-Years
35%
|
|
|
Hershey Co
NYSE:HSY
|
Net Issuance of Common Stock
-$503.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-1%
|
|
|
General Mills Inc
NYSE:GIS
|
Net Issuance of Common Stock
-$1.2B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
1%
|
|
|
Kellogg Co
NYSE:K
|
Net Issuance of Common Stock
$213m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kraft Heinz Co
NASDAQ:KHC
|
Net Issuance of Common Stock
-$988m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mondelez International Inc
NASDAQ:MDLZ
|
Net Issuance of Common Stock
-$2.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-3%
|
|
Lifecore Biomedical Inc
Glance View
Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. The company is headquartered in Chaska, Minnesota and currently employs 689 full-time employees. The firm offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials, as well as the manufacture of pharmaceutical-grade Hyaluronic Acid. The company provides complete CDMO services for injectable pharmaceuticals and medical devices. The Company’s services include sodium hyaluronate, development, manufacturing, and analytical services. The company offers a range of average molecular weights and custom modifications for research and development (R&D), clinical, and commercial applications. The Company’s therapeutic applications include drug delivery, biomaterials, ophthalmology, orthopedics, aesthetics, oncology, and pain management. Its development capabilities include formulation, sterile filtration, filling, packaging, testing, and secondary sterilization.
See Also
What is Lifecore Biomedical Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
23.8m
USD
Based on the financial report for Nov 24, 2024, Lifecore Biomedical Inc's Net Issuance of Common Stock amounts to 23.8m USD.
What is Lifecore Biomedical Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
35%
Over the last year, the Net Issuance of Common Stock growth was -38%.
You don't have any saved screeners yet